Occupation: Research House
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants.
Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries.
Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).
Run by a team of highly experienced professionals, our aim is to provide the research of choice for companies, investment banks and institutional investors. We provide independent reports, forecasts and valuations on each company we cover. We help clients gain access to investors, and facilitate feedback from the investment community on companies, their management and strategies. Our research strives to be objective, insightful, financially rigorous, readable and timely.
Web Address: http://www.edisongroup.com
280 High Holborn
Tel: Tel: +44 (0)20 3077 5700
AcenciA Debt Strategies (ACD), a closed-ended investment company, provides exposure to a range of mainly debt-oriented strategies via a portfolio of carefully selected hedge funds. These managers are generally closed to new investment and actively seek to exploit both long and short opportunities with the potential to benefit from positive, negative or more volatile markets. ACD therefore provides a differentiated proposition with the option for…
Brady has released an encouraging trading update and provides an upbeat outlook with a sales pipeline that remains strong. The company says H1 trading has been in line with management’s expectations with profit margins bouncing back. As we noted in March, £2.2m of costs were cut across the business in H213, although the group has had to invest more in the Commodities unit to deliver…
Regeneus has added another project to its portfolio, with licensing of global rights to an autologous human cancer vaccine that is expected to enter the clinic in Q115. Developed at the Kolling Institute, Sydney, the technology was already licensed to Regeneus for veterinary applications (Kvax), which is now in a US marketing trial for osteosarcoma in dogs. Cancer immunotherapy, including multiple approaches to cancer vaccines,…
AFH is delivering its strategy of organic and inorganic growth with H1FY14 on H1FY13 revenue up 50%, administration expenses up 47%, EBITDA up 97% and pre-tax profit up 55%. The cost growth included heavy investment for future growth as well as the impact of historic acquisitions (including intangible amortisation). AFH’s business model is differentiated from other quoted IFAs and its low gearing differentiates it from…
An impressive set of results for investors who bought into last July’s IPO is matched by management’s serious engagement with the fundamentals of a sustainable franchise. Real progress is being made across a range of strategic objectives, which we anticipate will strengthen franchise development going forward. In valuation terms the shares compare favourably with peers when the ungeared status is recognised, and the 5% yield…